Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Shares Outstanding (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Shares Outstanding for 8 consecutive years, with $24.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 193.66% to $24.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.1 million through Dec 2025, up 193.66% year-over-year, with the annual reading at $24.1 million for FY2025, 193.66% up from the prior year.
  • Shares Outstanding for Q4 2025 was $24.1 million at Precision Biosciences, up from $12.1 million in the prior quarter.
  • The five-year high for Shares Outstanding was $111.7 million in Q3 2022, with the low at $2.1 million in Q4 2021.
  • Average Shares Outstanding over 5 years is $28.7 million, with a median of $9.4 million recorded in 2024.
  • The sharpest move saw Shares Outstanding tumbled 96.54% in 2023, then soared 193.66% in 2025.
  • Over 5 years, Shares Outstanding stood at $2.1 million in 2021, then skyrocketed by 81.11% to $3.7 million in 2022, then rose by 12.49% to $4.2 million in 2023, then soared by 95.72% to $8.2 million in 2024, then skyrocketed by 193.66% to $24.1 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $24.1 million, $12.1 million, and $11.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.